Back to library
PharmaceuticalApproved

Semaglutide (Ozempic / Rybelsus)

seh-MAG-loo-tide

Research profile · How we handle evidence

Category

Pharmaceutical

Compound type

Phase / Status

Approved

FDA-approved with substantial human clinical-trial data

Standard Dose

0.25–2 mg weekly (Ozempic) or 3–14 mg daily (Rybelsus) - depends on indication and titration

Once weekly (injectable) or once daily (oral) when prescribed

Half-life

~168 hours (long-acting formulation)

Plasma elimination

Route(s)

IN / OR

Injectable or Oral (Tablets, Product Dependent)

Research Stage

Market Approved

Regulatory approval granted; post-market monitoring ongoing.

Overview

Semaglutide helps your body feel fuller and reduces blood-sugar spikes. People often describe it as turning down appetite signals - at first it can feel tough on the stomach.

Plain-language summary

Semaglutide helps your body feel fuller and reduces blood-sugar spikes. People often describe it as turning down appetite signals - at first it can feel tough on the stomach.

Administration Routes

  • Injectable
  • Oral (Tablets, Product Dependent)

Also known as

OzempicWegovyRybelsusSemaGLP-1 shotGLP-1 agonistThe Weight Loss ShotOzempic penHollywood drug

Mechanisms

1

GLP-1 receptor agonist

Detailed mechanism

Semaglutide is a long-acting GLP-1 receptor agonist. By activating GLP-1 receptors, it can: (1) increase glucose-dependent insulin secretion, (2) reduce glucagon secretion, (3) slow gastric emptying, and (4) promote satiety through brain and gut signaling. Together, these effects can reduce blood-sugar spikes and appetite, supporting weight loss.

Safety

Side effects

  • Nausea (most common, often improves over time)
  • Vomiting or diarrhea
  • Constipation, indigestion, or abdominal discomfort
  • Reduced appetite and slower stomach emptying (can contribute to feeling full quickly)
  • Gallbladder problems have been reported in weight-loss contexts
  • Seek urgent medical care for severe, persistent abdominal pain (possible pancreatitis - uncommon but important)

Reported benefits

  • Improves blood sugar control (type 2 diabetes)
  • Can support clinically meaningful weight loss
  • May reduce cardiovascular risk in appropriate patients (based on trial evidence)
  • Once-weekly dosing is convenient for many users

Safety profile

Most common adverse effects are gastrointestinal and often appear during initiation or dose escalation. Rare but serious risks (e.g., pancreatitis, gallbladder complications) require medical attention if symptoms are severe or persistent.

Clinical trials

Key programs include SUSTAIN (type 2 diabetes) and STEP (weight management), with additional cardiovascular outcomes data in appropriate populations.

Structure

View 3D structure

Verified structure

Semaglutide (Ozempic / Rybelsus)

Exact 2D structure can be rendered from a PubChem-backed canonical SMILES string.

Verified via PubChemMatched by casNumber
Source: PubChemLookup: 910463-68-2InChIKey DLSWIYLPEUIQAV-CCUURXOWSA-N
Chemical Formula
C187H291N45O59
Molecular Weight
4,114 g/mol
CAS Number
910463-68-2
InChIKey
DLSWIYLPEUIQAV-CCUURXOWSA-N

Stack Context

No stack data available.

References

  1. 1

    Semaglutide and cardiovascular outcomes in type 2 diabetes - SUSTAIN-6 trial (NEJM)

    2016

    View source
  2. 2

    Once-weekly semaglutide in adults with overweight or obesity - STEP-1 trial (NEJM)

    2021

    View source
  3. 3

    Cardiovascular outcomes with semaglutide 2.4mg in overweight adults without diabetes - SELECT trial (NEJM)

    2023

    View source

This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.

Research-driven insights.Evidence-based decisions.